1. Home
  2. UCL vs CALC Comparison

UCL vs CALC Comparison

Compare UCL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$1.70

Market Cap

74.5M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$5.33

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
CALC
Founded
2014
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.5M
88.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
UCL
CALC
Price
$1.70
$5.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
23.8K
105.2K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
8.06
N/A
EPS
0.12
N/A
Revenue
$85,239,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.86
N/A
P/E Ratio
$14.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.42
52 Week High
$4.19
$7.20

Technical Indicators

Market Signals
Indicator
UCL
CALC
Relative Strength Index (RSI) 42.51 51.20
Support Level $1.95 $5.55
Resistance Level $1.90 $7.20
Average True Range (ATR) 0.17 0.75
MACD -0.02 -0.11
Stochastic Oscillator 18.55 31.25

Price Performance

Historical Comparison
UCL
CALC

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: